115 related articles for article (PubMed ID: 12618896)
1. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial.
Feun LG; O'Brien C; Molina E; Rodriguez M; Jeffers L; Schiff ER; Marini A; Savaraj N; Ardalan B
J Cancer Res Clin Oncol; 2003 Jan; 129(1):17-20. PubMed ID: 12618896
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma.
Feun LG; Savaraj N; Hung S; Reddy R; Jeffers L; Benedetto P; Livingstone AS; Ardalan B; Levi JU; Parker T
Am J Clin Oncol; 1994 Oct; 17(5):393-5. PubMed ID: 8092109
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
4. Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Yau T; Chan P; Pang R; Ng K; Fan ST; Poon RT
Cancer; 2010 Nov; 116(21):5022-9. PubMed ID: 20629034
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Leung TW; Tang AM; Zee B; Yu SC; Lai PB; Lau WY; Johnson PJ
Cancer; 2002 Jan; 94(2):421-7. PubMed ID: 11905412
[TBL] [Abstract][Full Text] [Related]
8. [The chemotherapy for hepatocellular carcinoma].
Nagano H; Sakon M; Monden M
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1895-900. PubMed ID: 14650956
[TBL] [Abstract][Full Text] [Related]
9. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma.
Kardinal CG; Moertel CG; Wieand HS; Schutt AJ; O'Connell MJ; Wright K; Wiesenfeld M; Tschetter LK; Krook JE
Cancer; 1993 Apr; 71(7):2187-90. PubMed ID: 8384064
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
Creagan ET; Frytak S; Long HJ; Kvols LK
Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
Tsimberidou AM; Moulder S; Fu S; Wen S; Naing A; Bedikian AY; Daring S; Uehara C; Ng C; Wallace M; Camacho L; Kurzrock R
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1087-93. PubMed ID: 20204368
[TBL] [Abstract][Full Text] [Related]
13. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
[TBL] [Abstract][Full Text] [Related]
16. A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma.
Seki S; Yamada T; Kawakita N; Masuichi H; Kitada T; Sakaguchi H
Hepatogastroenterology; 2003; 50(53):1598-602. PubMed ID: 14571794
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
18. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Richly H; Schultheis B; Adamietz IA; Kupsch P; Grubert M; Hilger RA; Ludwig M; Brendel E; Christensen O; Strumberg D
Eur J Cancer; 2009 Mar; 45(4):579-87. PubMed ID: 19101137
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Akçali Z; Akin E; Ozyilkan O
Cancer; 2002 Nov; 95(9):2038-9; author reply 2039. PubMed ID: 12404300
[No Abstract] [Full Text] [Related]
[Next] [New Search]
